Studying mood changes in inflammatory arthritis patients on biologics
Treatments studied
Part of Bones, joints & muscles, Mental health, Skin clinical trials.
This study looks at how mood disorders (like depression or anxiety) affect people with chronic inflammatory joint diseases when they use biologic medicines. It may help doctors understand which patients are at higher mood-risk and how to monitor them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have one of these diagnoses: rheumatoid arthritis, axial or peripheral spondyloarthritis, ankylosing spondylitis, or psoriatic arthritis
- You can sign the consent form and agree to follow study visits and procedures
- You have French social security coverage (or another plan that counts as equivalent)
- You have not used anti-TNF medicines before (anti-TNF is a specific type of biologic)
- You are not currently pregnant and have no known depression or other psychiatric condition needing treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well people with rheumatoid arthritis (RA) take their RA medicines—especially medicines like methotrexate and other targeted or biologic treatments. It may help improve medication adherence (taking doses correctly) and supports safer, more consistent treatment at home.
This study looks at how chronic inflammatory illnesses progress over time and how treatments affect symptoms and disease markers. You may be invited if you’re receiving care for certain bowel, joint, or skin inflammatory conditions at the hospital.
This study is looking for people with ankylosing spondylitis, rheumatoid arthritis, or lupus to help find biomarkers that may make diagnosis easier. If you have one of these conditions and haven't tried biologic therapies, you may be able to join.
This study looks at how inflammatory “cytokines” are expressed in people with psoriasis—both those with joint involvement and those without. It may help researchers understand what drives joint disease and guide better future monitoring or treatments.
This study follows people who are at high risk for developing rheumatoid arthritis, as well as first-degree relatives of RA patients and people with very early untreated RA. It aims to learn more about the disease so doctors can better predict and prevent it.
This trial studies an add-on treatment approach for rheumatoid arthritis (RA) in adults whose symptoms did not improve with standard “first-line” medicines. It may help people who still have active RA after trying certain disease-modifying drugs.
Hear when a new Rheumatic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.